December 2023. Casgevy arrives: the first CRISPR therapy to rewrite faulty hemoglobin genes. Price tag: $2.2 million per patient. Gene-editing medicine is here. So is its velvet rope.
That same month, a startup called Orchid Biosciences launched a service enabling IVF couples to screen embryos for polygenic traits: not just single-gene diseases, but pred…
